IL6R and malignant colon neoplasm: Since the majority of sIL-6R is derived from proteolysis mediated by the metalloprotease ADAM17 [13–15], we knocked down ADAM17 with siRNA to verify its regulatory effect on sIL-6R release in colon cancer cells.